Effects of metabolic syndrome on onset age and long-term outcomes in patients with acute coronary syndrome

doi:10.5847/wjem.j.1920-8642.2021.01.006

Abstract

Abstract:

BACKGROUND: We aim to investigate effects of metabolic syndrome on onset age and long-term outcomes in patients with acute coronary syndrome (ACS).

METHODS: Patients with ACS (n=6,431) who underwent percutaneous coronary intervention from January to December 2013 were enrolled. After excluding patients with previous coronary artery disease, 1,558 patients were diagnosed with early-onset ACS (men aged ≤50 years; women aged ≤60 years) and 3,044 patients with late-onset ACS. Baseline characteristics and five-year clinical outcomes were measured.

RESULTS: Body mass index, triglyceride, low-density lipoprotein cholesterol, and uric acid concentrations were significantly higher, while the high-density lipoprotein cholesterol (HDL-C) concentration was lower in the early-onset ACS group (P<0.001). Multivariate logistic regression revealed obesity (odds ratio [OR] 1.590, 95% confidence interval [CI] 1.345-1.881), hypertriglyceridemia (OR 1.403, 95% CI 1.185-1.660), and low HDL-C (OR 1.464, 95% CI 1.231-1.742) as independent risk factors for early-onset ACS (all P<0.001). The five-year follow-up showed that the incidences of all cause death (1.5% vs. 3.8%, P<0.001), cardiac death (1.1% vs. 2.0%, P=0.023), and recurrent stroke (2.2% vs. 4.2%, P<0.001) were lower, while bleeding events were more frequent in the early-onset ACS group. A subgroup analysis showed higher incidences of recurrent myocardial infarction (MI) and revascularization in patients with early-onset ACS and metabolic syndrome.

CONCLUSIONS: Obesity, hypertriglyceridemia, and lower HDL-C level are independent risk factors for early-onset ACS, recurrent MI, and revascularization. The control of metabolic syndrome may reduce the incidence of early-onset ACS and improve the long-term prognosis.

Key words: Age, Coronary artery disease, Acute coronary syndrome, Metabolic syndrome

Jing-jing Xu, Ying Song, Ping Jiang, Lin Jiang, Xue-yan Zhao, Zhan Gao, Jian-xin Li, Shu-bin Qiao, Run-lin Gao, Yue-jin Yang, Yin Zhang, Bo Xu, Jin-qing Yuan. Effects of metabolic syndrome on onset age and long-term outcomes in patients with acute coronary syndrome[J]. World Journal of Emergency Medicine, 2021, 12(1): 36-41.

Figures/Tables 4

Table 1

Patients’ baseline characteristics between two groups

Parameters	Early-onset ACS (n=1,558)	Late-onset ACS (n=3,044)	P-value
Demographics
Age (years)	47.27±6.30	63.17±7.60	<0.001^*
Female, n (%)	404 (25.9)	737 (24.2)	0.201
BMI (kg/m²)	26.49±3.31	25.51±3.13	<0.001^*
Risk factors and medical history, n (%)
Hypertension history	946 (60.7)	1,959 (64.4)	0.016^*
Diabetes mellitus	391 (25.1)	866 (28.4)	0.016^*
Hyperlipidemia	1,103 (65.0)	1,915 (62.9)	0.159
Family history of CAD	431 (27.7)	690 (22.7)	<0.001^*
Smoking history	895 (57.4)	1,696 (55.7)	0.510
Previous stroke	79 (5.1)	392 (12.9)	<0.001^*
Peripheral vascular disease	16 (1.0)	69 (2.3)	0.003^*
Examination
White blood cell count before PCI (×10⁹/L)	7.12±1.91	6.90±1.85	<0.001^*
HGB before PCI (g/L)	143.46±15.43	139.26±16.27	<0.001^*
PLT before PCI (×10⁹/L)	223.58±57.09	206.97±56.22	<0.001^*
HbAlc (%)	6.53±1.33	6.56±1.18	0.483
B-brain natriuretic peptide (pg/mL)	680.73±386.46	804.05±719.57	<0.001^*
Big endothelin (pmol/L)	0.26±0.22	0.29±0.27	<0.001^*
Erythrocyte sedimentation rate (mm/h)	11.35±11.46	12.51±12.66	0.003^*
TC (mmol/L)	4.35±1.13	4.21±0.99	<0.001^*
LDL-C (mmol/L)	2.62±0.96	2.52±0.85	<0.001^*
HDL-C (mmol/L)	0.98±0.27	1.05±0.29	<0.001^*
Triglyceride (mmol/L)	2.04±1.27	1.70±0.97	<0.001^*
Uric acid (μmol/L)	348.50±87.75	334.56±83.25	<0.001^*
eGFR (mL/[minute·1.73 m²])	100.82±11.81	87.36±14.11	<0.001^*
LVEF (%)	63.52±6.54	63.27±6.78	0.229
Angiographic and procedural characteristics
LM or 3-vessel disease, n (%)	60 (3.9)	124 (4.1)	0.715
Complex lesion (lesion of type B2 or C), n (%)	1,158 (74.3)	2,291 (75.3)	0.488
Bifurcation disease, n (%)	308 (19.8)	582 (19.1)	0.598
Occlusion disease, n (%)	323 (20.7)	524 (17.2)	0.004^*
Syntax score	11.11±7.42	11.97±7.89	<0.001^*
Number of target lesion	1.41±0.68	1.41±0.65	0.632
Number of stents per patient	1.78±1.11	1.83±1.05	0.127
Antiplatelet therapy duration
Aspirin duration >1 year, n (%)	1,533 (98.4)	2,965 (97.1)	0.008^*
Clopidogrel duration >1 year, n (%)	1,502 (96.4)	2,921 (96.0)	0.459
Dual antiplatelet therapy >1 year, n (%)	1,067 (68.5)	2,016 (66.2)	0.123
ACS type, n (%)
STEMI	436 (28.0)	637 (20.9)	<0.001^*
NSTEMI	128 (8.2)	241 (7.9)	0.502
UA	994 (63.8)	2,166 (71.2)	<0.001^*

Table 1

Table 2

Table 3

Figure 1.

References 18

1	Sadeghi R, Adnani N, Erfanifar A, Gachkar L, Maghsoomi Z. Premature coronary heart disease and traditional risk factors — can we do better? Int Cardiovasc Res J. 2013; 7(2):46-50. pmid: 24757620
2	Jeemon P, Harikrishnan S, Sanjay G, Sivasubramonian S, Lekha TR, Padmanabhan S, et al. A programme of lifestyle intervention in families for cardiovascular risk reduction (PROLIFIC study): design and rationale of a family based randomized controlled trial in individuals with family history of premature coronary heart disease. BMC Public Health. 2017; 17(1):10. doi: 10.1186/s12889-016-3928-6 pmid: 28056897
3	Kalantzi K, Korantzopoulos P, Tzimas P, Katsouras CS, Goudevenos JA, Milionis HJ. The relative value of metabolic syndrome and cardiovascular risk score estimates in premature acute coronary syndromes. Am Heart J. 2018; 155(3):534-40. doi: 10.1016/j.ahj.2007.10.038 pmid: 18294493
4	Mirza AJ, Taha AY, Khdhir BR. Risk factors for acute coronary syndrome in patients below the age of 40 years. Egypt Heart J. 2018; 70(4):233-5. doi: 10.1016/j.ehj.2018.05.005 pmid: 30591735
5	Winter MP, Blessberger H, Alimohammadi A, Pavo N, Huber K, Wojta J, et al. Long-term outcome and risk assessment in premature acute myocardial infarction: a 10-year follow-up study. Int J Cardiol. 2017; 240:37-42. doi: 10.1016/j.ijcard.2017.03.146 pmid: 28395980
6	Brscic E, Bergerone S, Gagnor A, Colajanni E, Matullo G, Scaglione L, et al. Acute myocardial infarction in young adults: prognostic role of angiotensin — converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up. Am Heart J. 2000; 139(6):979-84. doi: 10.1067/mhj.2000.106165 pmid: 10827377
7	Do R, Stitziel NO, Won HH, Jørgensen AB, Duga S, Angelica Merlini P, et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015; 518(7537):102-6. doi: 10.1038/nature13917 pmid: 25487149
8	Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Glob Heart. 2012; 7(4):275-95. pmid: 25689940
9	Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115(17):2344-51. doi: 10.1161/CIRCULATIONAHA.106.685313 pmid: 17470709
10	Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011; 123(23):2736-47. pmid: 21670242
11	Kostara CE, Papathanasiou A, Psychogios N, Cung MT, Elisaf MS, Goudevenos J, et al. NMR-based lipidomic analysis of blood lipoproteins differentiates the progression of coronary heart disease. J Proteome Res. 2014; 13(5):2585-98. doi: 10.1021/pr500061n pmid: 24689886
12	Centers for Disease Control and Prevention (CDC). Prevalence of coronary heart disease — United States, 2006-2010. MMWR Morb Mortal Wkly Rep. 2011; 60(40):1377-81. pmid: 21993341
13	Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364(9438):937-52. doi: 10.1016/S0140-6736(04)17018-9 pmid: 15364185
14	Fernando H, Adams N, Mitra B. Investigations for the assessment of adult patients presenting to the emergency department with supraventricular tachycardia. World J Emerg Med. 2020; 11(1):54-9. pmid: 31893004
15	Ertelt K, Généreux P, Mintz GS, Brener SJ, Kirtane AJ, McAndrew TC, et al. Clinical profile and impact of family history of premature coronary artery disease on clinical outcomes of patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: analysis from the HORIZONS-AMI trial. Cardiovasc Revasc Med. 2014; 15(8):375-80. doi: 10.1016/j.carrev.2014.09.002 pmid: 25288517
16	Aggarwal A, Srivastava S, Velmurugan M. Newer perspectives of coronary artery disease in young. World J Cardiol. 2016; 8(12):728-34. pmid: 28070240
17	Alexander CM, Landsman PB, Teutsch SM, Haffner SM, Third National Health and Nutrition Examination Survey (NHANESIII), National Cholesterol Education Program (NCEP). NCEP defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003; 52(5):1210-4. pmid: 12716754
18	Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003; 108(4):414-9. pmid: 12860911

Parameters	OR	95% CI	P-value
Female	1.470	1.219-1.774	<0.001^*
Obesity (body mass index ≥28 kg/m²)	1.590	1.345-1.881	<0.001^*
Hypertension	0.697	0.596-0.817	<0.001^*
Diabetes mellitus	0.808	0.683-0.955	0.012^*
Hypertriglyceridemia (triglyceride ≥1.7 mmol/L)	1.403	1.185-1.660	<0.001^*
Low HDL-C (HDL-C <1.04 mmol/L)	1.464	1.231-1.742	<0.001^*
Family history of coronary artery disease	1.247	1.078-1.443	0.003^*
Smoking	1.097	0.940-1.282	0.240
Total cholesterol	1.089	0.907-1.308	0.361
LDL-C	1.004	0.820-1.229	0.971
Uric acid	1.002	1.000-1.002	0.002^*
Three to five metabolic syndrome components	1.902	0.863-1.381	0.465

Parameters	Hospitalization events			Five-year follow-up events
Parameters	Early-onset ACS (n=1,558)	Late-onset ACS (n=3,044)	P-value	Early-onset ACS (n=1,558)	Late-onset ACS (n=3,044)	P-value
MACCEs	18 (1.2)	51 (1.7)	0.169	262 (16.8)	662 (21.7)	<0.001^*
All-cause death	2 (0.1)	6 (0.2)	0.596	24 (1.5)	117 (3.8)	<0.001^*
Cardiac death	2 (0.1)	5 (0.2)	0.768	17 (1.1)	61 (2.0)	0.023^*
Recurrent myocardial infarction	17 (1.1)	45 (1.5)	0.281	81 (5.2)	191 (6.3)	0.143
Stent thrombosis	3 (0.2)	8 (0.3)	0.644	-	-	-
Target vessel revascularization	-	-	-	195 (12.5)	392 (12.9)	0.728
Recurrent stroke	0 (0)	0 (0)	1.000	34 (2.2)	127 (4.2)	0.001^*
Bleeding (BARC 2 to 5)	1 (0.1)	3 (0.1)	0.708	255 (16.4)	377 (12.4)	<0.001^*

[1]	Nelly Richter, Frank Bloos, Christian Hohenstein. Indications, techniques, success rates and complications of emergency airway management in Thuringian emergency departments: a prospective registry analysis [J]. World Journal of Emergency Medicine, 2026, 17(2): 146-153.
[2]	Paulo Henrique Reis Negreiros, Mariana Rebello Hilgert, Bruno Guerra, Maurício de Carvalho, Hugo Manuel Paz Morale, Gustavo Lenci Marques. The Brazilian risk assessment severity index score: a novel tool for predicting in-hospital mortality in emergency departments [J]. World Journal of Emergency Medicine, 2026, 17(2): 154-161.
[3]	Xing Luo, Jinzhao Zhang, Fanrong Lin, Siqi Liu, Zhengfei Yang. Beyond the chain of survival: a scoping review of artificial intelligence applications in cardiac arrest [J]. World Journal of Emergency Medicine, 2026, 17(1): 7-14.
[4]	Wei Gu, Jie Zhong, Chuanzhu Lyu, Guoqiang Zhang, Miaorong Xie, Yuefeng Ma, Wei Guo. An approach for the emergency diagnosis and treatment of sepsis-associated encephalopathy in elderly individuals: a literature review [J]. World Journal of Emergency Medicine, 2025, 16(5): 415-422.
[5]	Shin Ae Lee, Jongwon Ha, Ye Rim Chang. Defining optimal volume of inflation for partial resuscitative endovascular balloon occlusion of the aorta in swine hemorrhagic shock model [J]. World Journal of Emergency Medicine, 2025, 16(5): 431-437.
[6]	Sen Jiang, Xiandong Liu, Tong Liu, Yi Gu, Bo An, Chunxue Wang, Dongyang Zhao, Haitao Zhang, Lunxian Tang. Performance of a novel medical artificial intelligence large language model on supporting decision-making for emergency patients with suspected sepsis [J]. World Journal of Emergency Medicine, 2025, 16(5): 447-455.
[7]	Qingyuan Liu, Yixin Zhang, Jian Sun, Kaipeng Wang, Yueguo Wang, Yulan Wang, Cailing Ren, Yan Wang, Jiashan Zhu, Shusheng Zhou, Mengping Zhang, Yinglei Lai, Kui Jin. Early identification of high-risk patients admitted to emergency departments using vital signs and machine learning [J]. World Journal of Emergency Medicine, 2025, 16(2): 113-120.
[8]	Yi Zhu, Lina Mao, Zhongman Zhang, Sae Rom Lee, Tianshi Li, Hao Zhou, Yanbin Dong, Di An, Wei Li, Xufeng Chen. A predictive model for intracranial hemorrhage in adult patients receiving extracorporeal membrane oxygenation [J]. World Journal of Emergency Medicine, 2025, 16(2): 153-160.
[9]	Wachira Wongtanasarasin, Daniel K. Nishijima, Wanrudee Isaranuwatchai, Jeffrey S. Hoch. Real-world cost-effectiveness of targeted temperature management in out-of-hospital cardiac arrest survivors: results from an academic medical center [J]. World Journal of Emergency Medicine, 2025, 16(1): 28-34.
[10]	Rongde Lai, Shijiao Yan, Shijun Wang, Shuqing Yang, Zhangren Yan, Pin Lan, Yonggao Wang, Qi Li, Jinlong Wang, Wei Wang, Yuefeng Ma, Zijing Liang, Jianfeng Zhang, Ning Zhou, Xiaotong Han, Xinchao Zhang, Mao Zhang, Xiaodong Zhao, Guoqiang Zhang, Huadong Zhu, Xuezhong Yu, Chuanzhu Lyu. The Chinese guideline for management of snakebites [J]. World Journal of Emergency Medicine, 2024, 15(5): 333-355.
[11]	Jingyuan Xie, Jiandong Gao, Mutian Yang, Ting Zhang, Yecheng Liu, Yutong Chen, Zetong Liu, Qimin Mei, Zhimao Li, Huadong Zhu, Ji Wu. Prediction of sepsis within 24 hours at the triage stage in emergency departments using machine learning [J]. World Journal of Emergency Medicine, 2024, 15(5): 379-385.
[12]	Hao Li, Chang Liu, Ying Cui, Panpan Chang, Wei Chong. Effect of tubastatin A on NLRP3 inflammasome activation in macrophages under hypoxia/reoxygenation conditions [J]. World Journal of Emergency Medicine, 2024, 15(4): 289-296.
[13]	Zeyu Yang, Huiruo Liu, Dazhou Lu, Shengchuan Cao, Feng Xu, Chuanbao Li. Effects of high-dose glucose-insulin-potassium on acute coronary syndrome patients receiving reperfusion therapy: a meta-analysis [J]. World Journal of Emergency Medicine, 2024, 15(3): 181-189.
[14]	Yedalm Yoo, Shin Ahn, Bora Chae, Won Young Kim. Performance of the EDACS-ADP incorporating high-sensitivity troponin assay: Do components of major adverse cardiac events matter? [J]. World Journal of Emergency Medicine, 2024, 15(3): 175-180.
[15]	Jia Li, Jiazhen Luo, Tao Hu, Ling Cheng, Weiwei Shang, Li Yan. Impact of next-generation sequencing on antimicrobial treatment in immunocompromised adults with suspected infections [J]. World Journal of Emergency Medicine, 2024, 15(2): 105-110.